{"id":7093,"date":"2026-07-23T14:46:06","date_gmt":"2026-07-23T14:46:06","guid":{"rendered":"http:\/\/10.236.237.24\/?p=7093"},"modified":"2026-07-23T14:54:42","modified_gmt":"2026-07-23T14:54:42","slug":"masld","status":"publish","type":"post","link":"https:\/\/nhm.tn.gov.in\/ta\/masld\/","title":{"rendered":"Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD)"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"7093\" class=\"elementor elementor-7093\">\n\t\t\t\t<div class=\"elementor-element elementor-element-fb75dbd e-flex e-con-boxed e-con e-parent\" data-id=\"fb75dbd\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2868c3a0 elementor-widget elementor-widget-hfe-breadcrumbs-widget\" data-id=\"2868c3a0\" data-element_type=\"widget\" data-widget_type=\"hfe-breadcrumbs-widget.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<nav aria-label=\"Breadcrumb\"><ul class=\"hfe-breadcrumbs hfe-breadcrumbs-show-home\"><li class=\"hfe-breadcrumbs-item hfe-breadcrumbs-first\"><span class=\"hfe-breadcrumbs-home-icon\"><\/span><a href=\"https:\/\/nhm.tn.gov.in\/ta\"><span class=\"hfe-breadcrumbs-text\">Home<\/span><\/a><\/li><\/ul><\/nav>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-115aae e-flex e-con-boxed e-con e-parent\" data-id=\"115aae\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-b99002f e-con-full e-flex e-con e-child\" data-id=\"b99002f\" data-element_type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-57655ea1 e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"57655ea1\" data-element_type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;fadeInRight&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1e14311f elementor-widget elementor-widget-text-editor\" data-id=\"1e14311f\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h4 style=\"color: #734610; font-weight: 600;\">Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD)<\/h4>\n<div class=\"divider\"><\/div>\n\n<style>\na{\ntext-decoration:none;color:black;}\n<\/style>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2de3adc8 elementor-widget elementor-widget-text-editor\" data-id=\"2de3adc8\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div style=\"display: flex; justify-content: center;\"><img decoding=\"async\" class=\"alignnone wp-image-1163 size-full\" src=\"\"\" \/><\/div>\n&nbsp;\n<p style=\"font-weight: 400; text-align: justify:;\">Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD) is increasingly associated with metabolic risk factors such as obesity, diabetes mellitus, hypertension, and dyslipidemia, and can progress silently to advanced liver disease if not identified early. As per the Global Burden of Disease (GBD) Study 2023, the prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in India is 12.74%, while Tamil Nadu records a notably higher prevalence of ,16.09%, highlighting the greater burden of this condition in the State. Since the condition is often asymptomatic in its initial stages, early screening and risk stratification are essential for timely intervention and management.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD) is increasingly associated with metabolic risk factors such as obesity, diabetes mellitus, hypertension, and dyslipidemia, and can progress silently to advanced liver disease if not identified early. As per the Global Burden of Disease (GBD) Study 2023, the prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in India is 12.74%, while Tamil Nadu records a notably higher prevalence of ,16.09%, highlighting the greater burden of this condition in the State. Since the condition is often asymptomatic in its initial stages, early screening and risk stratification are essential for timely intervention and management.<\/p>","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-7093","post","type-post","status-publish","format-standard","hentry","category-nhm-programs"],"_links":{"self":[{"href":"https:\/\/nhm.tn.gov.in\/ta\/wp-json\/wp\/v2\/posts\/7093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhm.tn.gov.in\/ta\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhm.tn.gov.in\/ta\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhm.tn.gov.in\/ta\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/nhm.tn.gov.in\/ta\/wp-json\/wp\/v2\/comments?post=7093"}],"version-history":[{"count":0,"href":"https:\/\/nhm.tn.gov.in\/ta\/wp-json\/wp\/v2\/posts\/7093\/revisions"}],"wp:attachment":[{"href":"https:\/\/nhm.tn.gov.in\/ta\/wp-json\/wp\/v2\/media?parent=7093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhm.tn.gov.in\/ta\/wp-json\/wp\/v2\/categories?post=7093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhm.tn.gov.in\/ta\/wp-json\/wp\/v2\/tags?post=7093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}